Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All drugs

HMPL-306 (ranosidenib)

Stage Phase 3

Sponsor Hutchmed

Route oral

Modality small molecule

Class mutant IDH1/IDH2 inhibitor

Target IDH1 R132 (mutant)

Target IDH2 R172 (mutant)

Sources

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT07912398

ClinicalTrials.gov NCT07912398, HMPL-306 (ranosidenib) vs placebo Phase 3 in IDH-mutant grade 2 or 3 glioma, API v2 record retrieved 11.07.2026; China CTR20263911 (registry)

Brief source I15

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT07912398

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of HMPL-306 in Participants With Postoperative Residual or Recurrent Grade 2 Glioma Harboring IDH1 or IDH2 Mutations

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT07025018

A Multicenter, Randomized Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of HMPL-306 in Patients With Gliomas Harboring IDH1 and/or IDH2 Mutations

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

NCT07912398

Registry NCT07912398

Phase Phase 3

Status Not yet recruiting

Enrollment 210

Start 2026-11

Primary completion 2032-03

Study completion 2032-09

Catalyst Primary completion. 03.2032. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

HMPL-306 250 mg QD

Dose 250 mg

Regimen once daily

Comparator placebo

Population IDH-mutant grade 2 or 3 glioma (n = 210)

Estimand ITT

NCT07025018

Registry NCT07025018

Phase Phase 1

Status Recruiting

Enrollment 52

Start 2025-07-15

Primary completion 2026-12

Study completion 2027-12

Catalyst Primary completion. 12.2026. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.